Company intelligence / Profile preview

BioControl Medical

Yehud, Tel Aviv District, Israelbiocontrol-medical.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The CardioFit vagus nerve stimulation system has demonstrated safety and efficacy signals in pilot and pivotal studies for heart failure. It received CE mark approval in Europe and completed major enrollment milestones for its INOVATE-HF trial in the US. As of last reports, it remained investigational under FDA oversight with no full market approval yet. Earlier devices also targeted urinary disorders.

Therapeutic areas: CardiovascularNeurology
Modalities: DeviceElectrical nerve stimulation device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

CardioFit

Phase 3

Indications: Heart failure

Partnerships

No major pharmaceutical partnerships publicly disclosed; collaborations with leading academic medical centers such as Mount Sinai Hospital noted during clinical trials.

Beyond the preview

Go deeper on BioControl Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioControl Medical.

Explore the full profile